Furthermore, studies conducted by Gan et al. [127], Haruki et al. [128], Li et al. [129], Meira Junior et al. [130], Shen et al. [131], and Iida et al. [132] demonstrated that a high pre-treatment serum lactic dehydrogenase (LDH)/ALB ratio, serum prothrombin time–international normalized ratio (PT-INR)/ALB ratio, serum PLT/ALB ratio, serum PLT–ALB grade, serum neutrophil to lymphocyte ratio (NLR)/ALB ratio, and a low pre-treatment serum CRP-ALB-lymphocyte (LYM) index independently predicted worse OS, DFS, and RFS in HCC patients treated with curative surgical resection. The gene discussed is ALB; the disease is hepatocellular carcinoma.